Does eribulin mesylate have potential in mCRPC … or not?

In May 2010 we reported that a product called eribulin mesylate had been tested (in the USA) in a Phase II clinical trial for its activity in metastatic, castration-resistant prostate cancer (mCRPC) — and that the results were not particularly promising. … READ MORE …

More data to come at ASCO in June

We commented earlier today on the positive data about tasquinimod that will be presented at the ASCO annual meeting. Negative data will unfortunately be presented on other drugs, but not everything is doom and gloom. … READ MORE …